abcam

ab31844

Anti-Cytokeratin 18 antibody [LDK18]

Key facts

Isotype	IgG1
Host species	Mouse
Storage buffer	Preservative: 0.02% Sodium azide Constituents: PBS
Form	Liquid
Clonality	Monoclonal
Immunogen	Synthetic Peptide within Human KRT18 aa 400 to C-terminus. The exact immunogen used to generate this antibody is proprietary information. Database link P05783
Clone number	LDK18
Purification technique	Affinity purification Protein A/G
Concentration	1 mg/mL The concentration of this product may be batch-dependent Batch concentration finder →

Reactivity data

Flow Cyt

Tested

Species	Human
Dilution info	0.1 µg for 10^6 Cells
Notes	ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.

IHC-P

Tested

Species	Human
Dilution info	-
Notes	-

ICC/IF

Tested

Species	Human
Dilution info	5 µg/mL
Notes	-

Target data

See full target information KRT18

Function	Required for the formation of KRT8/KRT18 filaments that are involved in ARHGEF40-mediated actin stress fiber formation and tensional force-induced stress fiber formation and reinforcement (PubMed:26823019). Also acts downstream of ROCK kinase activation as part of a positive feedback mechanism in response to cellular mechanical stress loading (PubMed:26823019). Organization and orientation of KRT18 filaments are responsible for the properly elongated morphology of epithelial tubules (By similarity). Involved in the uptake of thrombin-antithrombin complexes by hepatic cells (By similarity). When phosphorylated, plays a role in filament reorganization. Involved in the delivery of mutated CFTR to the plasma membrane. Together with KRT8, is involved in interleukin-6 (IL-6)-mediated barrier protection.

Storage

Shipped at conditions	Blue Ice
Appropriate short-term storage duration	1-2 weeks
Appropriate short-term storage conditions	+4°C

Appropriate long-term storage conditions	-20°C
Aliquoting information	Upon delivery aliquot
Storage information	Avoid freeze / thaw cycle

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary	Cytokeratin 18 (CK18) also known as Keratin 18 or KRT18 is a type I intermediate filament protein with a molecular weight of approximately 45 kDa. It plays a mechanical role in stabilizing epithelial cell structure and function. CK18 is expressed in single-layered epithelial tissues such as the liver intestine and pancreas. It partners with the type II keratin usually KRT8 to form a stable cytoskeletal network in these cells providing structural integrity and resilience.
Biological function summary	CK18 maintains cellular integrity and mediates resistance to mechanical and non-mechanical stresses in epithelial cells. It forms heterodimers with KRT8 participating in a complex network of filaments important for maintaining cell shape and stability. This organization plays a role in managing cell survival during stress and apoptosis helping regulate cellular functions and responses in tissues where it is expressed.
Pathways	Cytokeratin 18 is involved in the apoptosis and cellular stress response pathways. It interacts with proteins such as caspases during apoptosis facilitating cytoskeletal reorganization and cell fragmentation. CK18 in coordination with KRT8 also participates in signaling pathways that regulate cell cycle and apoptotic processes underlining its importance in cellular turnover and tissue homeostasis.
Associated diseases and disorders	Elevated levels of CK18 fragments are often observed in cases of non-alcoholic steatohepatitis (NASH) and breast cancer. It serves as a biomarker for liver injury due to its abundance in hepatocytes and release upon cell death. In breast cancer alterations in CK18 expression can reflect disease progression where it interacts with other proteins such as vimentin indicating epithelial-to-mesenchymal transition a process that facilitates metastasis.

Product promise

Tested

We have tested this species and application combination and it works. It is covered by our product promise.

Expected

We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.

Predicted

This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.

Not recommended

We do not recommend this combination. It is not covered by our product promise.


We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

---


3 product images



Immunocytochemistry/ Immunofluorescence - Anti-Cytokeratin 18 antibody [LDK18] (ab31844)

Cytokeratin 18 Immunocytochemistry/ Immunofluorescence staining using mouse Anti-Cytokeratin 18 antibody


ICC/IF image of ab31844 stained HCT116 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab31844 at 5µg/ml overnight at +4°C. The secondary antibody (green) was DyLight® 488 goat anti- mouse (ab96879) IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.



Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Cytokeratin 18 antibody [LDK18] (ab31844)

Cytokeratin 18 Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) staining using mouse Anti-Cytokeratin 18 antibody

ab31844 staining human normal colon tissue. Staining is localised to cytoplasm.
Left panel: with primary antibody at 2 ug/ml. Right panel: isotype control.
Sections were stained using an automated system DAKO Autostainer Plus , at room temperature. Sections were rehydrated and antigen retrieved with the Dako 3-in-1 antigen retrieval buffer citrate pH 6.0 in a DAKO PT Link. Slides were peroxidase blocked in 3% H2O2 in methanol for 10 minutes. They were then blocked with Dako Protein block for 10 minutes (containing casein 0.25% in PBS) then incubated with primary antibody for 20 minutes and detected with Dako Envision Flex amplification kit for 30 minutes. Colorimetric detection was completed with diaminobenzidine for 5 minutes. Slides were counterstained with Haematoxylin and coverslipped under DePeX. Please note that for manual staining we recommend to optimize the primary antibody concentration and incubation time (overnight incubation), and amplification may be required.



Flow Cytometry - Anti-Cytokeratin 18 antibody [LDK18] (ab31844)

Cytokeratin 18 Flow Cytometry staining using mouse Anti-Cytokeratin 18 antibody

Overlay histogram showing MCF7 cells stained with ab31844 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab31844, 0.1µg/1x10^6 cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H&L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1µg/1x10^6 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive signal in MCF7 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.